Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations-Reference-Cited by-同舟云学术

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Published:2024-07 Issue:7 Volume:25 Page:e308-e317
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lim Annette M,Le Tourneau Christophe,Hurt Chris,Laskar Sarbani G,Steuer Conor E,Chow Velda L Y,Szturz Petr,Henson Christina,Day Andrew T,Bates James E,Lazarakis Smaro,McDowell Lachlan,Mehanna Hisham,Yom Sue S

Publisher

Elsevier BV

Reference37 articles.

1. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019

3. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

4. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study;Harrington;J Clin Oncol,2023

5. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials;Schulz;BMJ,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations;The Lancet Oncology;2024-07